56 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
100 cells/mm3 g/mL ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
suspension 4–6 mL ... for effective treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
Algorithm for the Treatment of Uremic Pruritus
Nonpharmacologic Treatments:
 • Daily topical emollient
 • Avoidance of extremes
Algorithm for the ... Treatment of Uremic ... Evidence-Based Off-Label Pharmacologic ... nalfurafine 2.5 mcg ... uremia #itching #Algorithm
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
if MIC<0.12 ug/ml ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
duration same as for treatment ... Disease Note: Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
Management of interstitial lung disease (ILD)-associated with systemic sclerosis (SSc)

Therapeutic indication: absolute decline in FVC >10%
>10% (or >200 mL ... DLCO >15% (or 3 mL ... Symptomatic treatment ... optimization of GERD treatment ... #algorithm